Why Legacy RTSM Systems Create Risk in Biosimilar Trials

Biosimilar trials create unique supply chain challenges, where high-cost comparator biologics, limited availability, and strict compliance requirements leave little room for error. Clinical supply teams must balance inventory efficiency with uninterrupted patient access while maintaining inspection readiness across increasingly complex global studies.

Modern RTSM technology can play a critical role in reducing comparator waste and improving operational control. By combining real-time inventory visibility, adaptive resupply strategies, forecasting integrations, and participant-level supply management, sponsors can better align supply decisions with actual study activity. Advanced capabilities such as cross-study pooling, end-to-end traceability, and AI-powered risk monitoring help teams identify emerging issues earlier, reduce manual oversight, and respond more effectively to changing enrollment patterns or sourcing constraints.

Organizations that embrace data-driven supply management often see measurable reductions in waste, stronger compliance confidence, and more stable study execution. Explore how smarter supply strategies can help biosimilar sponsors improve efficiency, protect continuity of dosing, and maintain greater control throughout the clinical trial lifecycle.